Your browser doesn't support javascript.
loading
Approval of Aducanumab for Alzheimer Disease-The FDA's Perspective.
Dunn, Billy; Stein, Peter; Cavazzoni, Patrizia.
Affiliation
  • Dunn B; US Food and Drug Administration, Silver Spring, Maryland.
  • Stein P; US Food and Drug Administration, Silver Spring, Maryland.
  • Cavazzoni P; US Food and Drug Administration, Silver Spring, Maryland.
JAMA Intern Med ; 181(10): 1276-1278, 2021 10 01.
Article in En | MEDLINE | ID: mdl-34254984
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain / Plaque, Amyloid / Dose-Response Relationship, Drug / Alzheimer Disease / Antibodies, Monoclonal, Humanized Type of study: Clinical_trials / Diagnostic_studies / Prognostic_studies Limits: Humans Country/Region as subject: America do norte Language: En Journal: JAMA Intern Med Year: 2021 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain / Plaque, Amyloid / Dose-Response Relationship, Drug / Alzheimer Disease / Antibodies, Monoclonal, Humanized Type of study: Clinical_trials / Diagnostic_studies / Prognostic_studies Limits: Humans Country/Region as subject: America do norte Language: En Journal: JAMA Intern Med Year: 2021 Document type: Article Country of publication: